About Us

Tablets packages

Our Goal

We are developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Our goal is for our small, oral protein tablets to change treatment outcomes for patients globally.

Our lead program is potentially the first oral osteoanabolic (bone forming) daily tablet to treat osteoporosis – a disease that disproportionately affects women and where current bone forming agents are only available in injectable formats.

We aspire to continue to validate our platform across a plethora of additional high value therapeutic proteins via our internal efforts and in collaboration with leading protein therapeutic companies.

Scientific Advisory Board

John P. Bilezikian, MD

Vice-Chair, Department of Medicine for International Research and Education; Chief, Emeritus, of the Division of Endocrinology; Director, Emeritus, of the Metabolic Bone Diseases Program at Columbia University Medical Center

Maria Luisa Brandi, MD, PhD

Professor of Endocrinology, FIRMO Foundation, Florence, Italy

Bart Clarke, MD

Professor of Medicine and Consultant, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic

Felicia Cosman, MD

Professor of Medicine, Emerita, Columbia University College of Physicians and Surgeons, Division of Endocrinology; Co-Editor in Chief of the journal Osteoporosis International

William Fraser, MD

Professor of Medicine and Deputy Head of Norwich Medical School at the University of East Anglia and Consultant in Metabolic Medicine at the Norfolk and Norwich University Hospital, UK

Roger Garceau, MD

Former Chief Medical Officer and EVP at NPS Pharmaceuticals and Shire plc (Natpara®); with previous senior management roles at Sanofi Aventis and Pharmacia

Sofia Ish-Shalom, MD

Vice President of the Israeli Foundation for Osteoporosis and Bone Diseases (IFOB), Endocrine Clinic Elisha Hospital; prior Head of Bone and Mineral Metabolism Unit, Rambam Health Care Campus, Haifa Israel

Socrates Papapoulos, MD

Emeritus Professor in Diseases of Bone & Mineral Metabolism, Advisor Center for Bone Quality, Leiden University Medical Center, The Netherlands

Steven R. Goldstein, MD

Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society.

Arthur Santora, MD, PhD

Clinical Associate Professor at Rutgers Robert Wood Johnson Medical School, NJ. Former Scientific Associate VP of Clinical Research at Merck. Served as a Medical Officer at the US FDA

Rachel B. Wagman, MD

Miranda Toledano

Chief Executive Officer

Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/ capital market experience in the biotech sector. Since 2018, Ms. Toledano served as a Member of the Board, Chair of the Audit Committee, and Member of the Compensation and Scientific Advisory Committee at Entera, and as CEO since July 2022. Previously, Miranda served as COO and CFO, and Director of TRIGR Therapeutics, a private oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and 

acquisition by CMPX 3 years after the Company’s founding. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX). Ms. Toledano is also a Director at Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Felicia Cosman, MD

Dr. Felicia Cosman is a clinical scientist, endocrinologist and osteoporosis specialist.  She is Professor of Medicine at Columbia University and has been North American Co-Editor in Chief of the journal Osteoporosis International since 2016.  She received a BA from Cornell, MD from Stony Brook Medical School, and completed internship, residency and endocrinology fellowship at Columbia University College of Physicians and Surgeons.  Throughout her career, Dr. Cosman has had many grants from the National Institutes of Health, the Department of Defense, multiple foundations and industry.  She has published over 190 peer-reviewed papers and over 50 book chapters and has been an Associate Editor for several osteoporosis textbooks, most recently the Fifth Edition of Marcus and Feldman’s Osteoporosis.

Dr. Cosman has been involved in many studies evaluating multiple therapeutic agents for osteoporosis. The main focus of her research has been the use of anabolic medications and treatment sequencing. 

 Dr. Cosman has investigated the effect of teriparatide on biochemical and densitometric outcomes, bone microarchitecture and strength, and cellular action using bone biopsy.  She performed a series of studies that investigated cyclic, combination and sequential regimens of teriparatide with antiresorptives, including bisphosphonates, denosumab, raloxifene and estrogen. She led a novel study evaluating the effect of teriparatide on bone formation in the human femur in patients undergoing hip arthroplasty. Dr. Cosman has also been a primary investigator on many studies evaluating the efficacy of abaloparatide and romosozumab treatment for osteoporosis.  She is well known for work on optimizing anabolic treatment regimens, longterm treatment strategies in postmenopausal women, and implementing therapeutic goals for osteoporosis management.

She received the ACE Distinction in Endocrinology Award in 2019 and the ASBMR Bartter Award for clinical research in September 2020.

Steven R. Goldstein, MD

Steven R. Goldstein, MD is on the Faculty of the Department of Obstetrics and Gynecology at New York University Grossman School of Medicine, as a Professor of Obstetrics and Gynecology. He is the immediate past President of the International Menopause Society. He is past President and Fellow of the American Institute of Ultrasound in Medicine. He is a past President of the North American Menopause Society (NAMS).

Dr. Goldstein has authored the International Menopause Society’s white paper on bone health. He has published seven books on women’s health topics, including menopause, perimenopause early pregnancy monitoring, abnormal uterine bleeding and gynecologic ultrasound. He has authored more than 60 chapters as well as over 140 original research articles.  

He is a past Chairman of the American College of Obstetrics and Gynecology, New York Section. He has been a guest faculty member, invited speaker, visiting professor or course director over 400 times throughout the United States and the world.

Dr. Goldstein is an Honorary Fellow of the Royal College of Obstetricians and Gynaecologists. He has received numerous awards such as the William J. Fry Memorial Lecture Award from the American Institute of Ultrasound in Medicine (AIUM) in 2023, the Ian Donald Gold Medal from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) in 2023, the Holmes Pioneer Award from AIUM in 2019, and the Clarkson Award from NAMS in 2016.

Gregory Burshtein, PhD

EVP, Head of R&D

Dr. Burshtein leads Research and Development at Entera since joining the Company in 2012, as Director of Pharmaceutical R&D.

Dr. Burshtein holds over 20 years of experience in the field of drug delivery, pharmacology and biopharmaceutics, with a primary focus on the challenging area of oral delivery of therapeutic peptides. 

Gregory is the inventor of many patents and has presented and authored multiple publications in peer-reviewed journals related to oral delivery of peptides.

Dr. Burshtein obtained his Ph.D. in Pharmaceutical Sciences, MSc in Clinical Pharmacy, and B. Pharm degree from the Institute for Drug Research, Faculty of Medicine of the Hebrew University of Jerusalem.

Hillel Galitzer, PhD

Chief Operating Officer

Dr. Hillel Galitzer has served as our Chief Operating Officer since February 2014, prior to which he served as our Director of Scientific Development from July 2012. Dr. Galitzer has more than ten years of experience in medical research and molecular biology. Between August 2010 and February 2014, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of 

Optivasive Inc. He has written numerous publications in peer-reviewed journals and has lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.

Dana Yaacov, CPA

Chief Financial Officer

Dana Yaacov-Garbeli has served as our Israel-based Chief Financial Officer since June 2019 and as the Company’s Chief Financial Officer effective as of July 15, 2022. Ms. Yaacov-Garbeli has over 15 years of chief finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She is an expert in financial planning, operations management, external and internal audit for 

public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli is also a partner at A2Z-Finance, a company that provides financial and accounting services. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.

Anke Hoppe

VP of Clinical Operations

Ms. Hoppe leads clinical operations at Entera since 2018. Ms. Hope has over 30 years of clinical operations experience in major international pharmaceutical and biopharmaceutical companies and various clinical research organizations. 

Her experience ranges from serving as clinical research associate (Sanofi for 9 years) to project management lead at several of the leading CROs and Vertex Pharmaceuticals.

Rachel B. Wagman, MD

Rachel B Wagman, MD, FACE, FACP, serves as key clinical advisor to Entera. Dr. Wagman brings more than 20 years of metabolic bone disease and women’s health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle management. Dr. Wagman’s clinical leadership experiences include progressive roles at Eli Lilly, Amgen, and Myovant Sciences, where as Senior Vice President Clinical Development, she integrated Myovant’s development portfolio into the newly-established Sumitomo Pharma America. 

She completed her BA at the University of Pennsylvania, MD at Jefferson Medical College, Internal Medicine residency at Thomas Jefferson University Hospital, and postdoctoral fellowship in Endocrinology, Gerontology, and Metabolism at Stanford University School of Medicine.

She is a Fellow of both the American College of Endocrinology and the American College of Physicians and holds dual board certifications in Internal Medicine and Endocrinology, Diabetes, and Metabolism.

Gerald Lieberman

Chairman of the Board

Gerald Lieberman has served as a member of our Board since April 2014 and became our Chairman in July 2019. Mr. Lieberman is also a member of the board of directors of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in pharmaceuticals and the world’s largest generic drug developer and manufacturer, where he chairs the Audit Committee and serves on both the Human Resources and Compensation Committee and the Finance Committee. He also serves as Chairman of the Board of Directors of DosenRx, Ltd., a Digital health company that has developed a personalized, patient-controlled device for delivering medication. He is also currently a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. From 2000 to 2009, Mr. Lieberman was an executive at Alliance Bernstein L.P., where he 

served as President and Chief Operating Officer from 2004 to 2009, as Chief Operating Officer from 2003 to 2004 and as  Executive Vice President, Finance and Operations from 2000 to 2003. From 1998 to 2000, he served as Senior Vice President, Finance and Administration at Sanford C. Bernstein & Co., Inc., until it was acquired by Alliance Capital in 2000, forming Alliance Bernstein L.P. Prior to that, he served in various executive positions at Fidelity Investments and at Citicorp. Prior to joining Citicorp he was a certified public accountant with Arthur Andersen. He previously served on the board of directors of Forest Laboratories, LLC from 2011 to 2014, Computershare Ltd. from 2010 to 2012 and Alliance Bernstein L.P. from 2004 to 2009. Mr. Lieberman received a B.S. Beta Gamma Sigma with honors in business from the University of Connecticut.

Sean Ellis

Sean Ellis has served as a member of our Board since June 2019. Mr. Ellis brings extensive knowledge of both life sciences and the U.S. financial markets, with a longstanding history in asset management. Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a 


primary focus on investments in the biotech and related healthcare industries. Centillion is one of Entera Bio’s earliest investors and largest shareholders. He holds a BA from New York University and MBA from Columbia University.

Haya Taitel

Ms. Taitel has over 30 years of global C-level biopharma commercial and strategic executive experience.  Ms. Taitel currently serves as the Head of Sanofi’s Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock®, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led 

Kadmon Board’s Executive Commercial  Committee. Beginning in 1997, Ms. Taitel had held various  commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women’s healthcare. Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel.

Yonatan Malca

Yonatan Malca has served as a member of our Board since 2011. Mr. Malca currently serves as a Chief Executive Officer and director of NanoGohst Ltd. Since 2010 until 2021, he served as a Chief Executive Officer and director of D.N.A Biomedical Mr. Malca also serves as a director of Nextgen-Biomed LTD. (TASE: 

NXGN) and Jungo Connectivity Ltd.(TASE: JNGO) , each of which is an Israeli public  company. Mr. Malca holds a B.A. in Economics and Statistics from Bar-Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel.

Roger Garceau, MD

Dr. Roger J. Garceau has served as a member of our Board since March 2016 and as our interim CEO From August 2020 to January 4, 2021. Dr. Garceau served also served as our Chief Development Advisor since December 2016 and until December 2021 (excluding the period he served as our interim CEO).. Dr. Garceau has more than 30 years of broad pharmaceutical industry experience. He has been a director of Enterome SA since December 2016, and a director of ArTara Therapeutics since January 2019. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December

2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals, Inc., then traded on Nasdaq, was acquired by Shire plc. (NASDAQ: SHPG). Previously, Dr. Garceau served in several managerial positions with Sanofi-Aventis (NYSE: SNY) from 2002 until 2008, and Pharmacia Corporation from 1986 until 2002. Dr. Garceau is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds a B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School. 

Ron Mayron

Ron Mayron has served as a member of our Board since April 2021 and is a global healthcare specialist who serves on the boards of numerous public and privately held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa from 2009 until 2013 and 

CEO of S.L.E from 1999 and until 2007. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben-Gurion University, and an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston.

Gerald M. Ostrov

Gerald M. Ostrov has served as a member of our Board since January 2019. Mr. Ostrov consults and invests in new technologies in the medical device and consumer products fields. Mr. Ostrov currently serves on the board of directors of several privately held companies, including Mother’s Choice, a natural products company working with industry giants, Addon Optics, an innovative technology company, and Nuvo, a developer of next generation baby and mother health monitoring for both hospital and home use. From 2008 to 2010, he served as Chairman and CEO of Bausch & Lomb. There Mr. Ostrov led the stabilization, streamlining and pipeline building of Bausch & Lomb following its going-private transaction.

From 1998 until 2006, Mr. Ostrov very successfully served as Company Group Chairman for Johnson & Johnson’s Worldwide Vision Care businesses. From 1991 to 1998, Mr. Ostrov worked for Johnson & Johnson and quickly rose to serve as Company Group Chairman of the Consumer and Personal Care businesses in North America. From 1982 to 1991, he served as President of CIBA Consumer Pharmaceuticals Company. From 1976 to 1982, he worked for the Health Care Division of Johnson & Johnson. From 1973 to 1976, Mr. Ostrov worked at Procter & Gamble. Mr. Ostrov holds a B.S. from Cornell and an M.B.A. from Harvard.

Thank You

Message Sent!

We will get back to you soon